U.S. Markets close in 14 mins
  • S&P 500

    4,244.37
    -3.07 (-0.07%)
     
  • Dow 30

    34,321.05
    -158.55 (-0.46%)
     
  • Nasdaq

    14,134.29
    +64.87 (+0.46%)
     
  • Russell 2000

    2,322.70
    -13.10 (-0.56%)
     
  • Crude Oil

    70.93
    +0.02 (+0.03%)
     
  • Gold

    1,866.80
    -12.80 (-0.68%)
     
  • Silver

    28.00
    -0.14 (-0.50%)
     
  • EUR/USD

    1.2123
    +0.0016 (+0.1333%)
     
  • 10-Yr Bond

    1.5010
    +0.0390 (+2.67%)
     
  • Vix

    16.66
    +1.01 (+6.45%)
     
  • GBP/USD

    1.4109
    -0.0007 (-0.0508%)
     
  • USD/JPY

    110.0800
    +0.4450 (+0.4059%)
     
  • BTC-USD

    39,705.05
    +2,140.56 (+5.70%)
     
  • CMC Crypto 200

    992.38
    +23.54 (+2.43%)
     
  • FTSE 100

    7,146.68
    +12.62 (+0.18%)
     
  • Nikkei 225

    29,161.80
    +213.07 (+0.74%)
     

ResMed Announces Participation in KeyBanc’s Capital Markets' Life Sciences & MedTech Investor Forum

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

ResMed (NYSE: RMD, ASX: RMD) today announced Rob Douglas, president and chief operating officer and Brett Sandercock, chief financial officer, will participate in a virtual fireside chat at the KeyBanc Capital Markets' Life Sciences & MedTech Investor Forum on Tuesday, March 23, 2021, beginning at approximately 4:15 p.m. (Eastern Daylight Time) via video webcast.

More information about this event, including access to the live webcast, may be accessed by visiting http://investor.resmed.com. The webcast replay will be available approximately one hour after the live webcast ends and will be accessible through June 21, 2021.

About ResMed

At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries. To learn more, visit ResMed.com and follow @ResMed.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210316005034/en/

Contacts

For investors
Amy Wakeham
+1 858.836.5000
investorrelations@resmed.com

For media
Jayme Rubenstein
+1 858.836.6798
news@resmed.com